Evaluation of large‐scale clinical trials on cardiovascular disease risk in patients with type 2 diabetes mellitus treated with dipeptidyl peptidase 4 inhibitors and a new class of drugs

Several recent prospective cardiovascular clinical trials completed with newly developed drugs for the treatment of type 2 diabetes mellitus have been published. Caution must be used when interpreting these studies.[Image: see text]

Detalles Bibliográficos
Autores principales: Kurose, Takeshi, Hamamoto, Yoshiyuki, Seino, Yutaka
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2017
Materias:
Editorial
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5583954/
https://www.ncbi.nlm.nih.gov/pubmed/28130883
http://dx.doi.org/10.1111/jdi.12635
_version_ 1783261378385018880
author Kurose, Takeshi
Hamamoto, Yoshiyuki
Seino, Yutaka
author_facet Kurose, Takeshi
Hamamoto, Yoshiyuki
Seino, Yutaka
author_sort Kurose, Takeshi
collection PubMed
description Several recent prospective cardiovascular clinical trials completed with newly developed drugs for the treatment of type 2 diabetes mellitus have been published. Caution must be used when interpreting these studies.[Image: see text]
format Online
Article
Text
id pubmed-5583954
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-55839542017-09-06 Evaluation of large‐scale clinical trials on cardiovascular disease risk in patients with type 2 diabetes mellitus treated with dipeptidyl peptidase 4 inhibitors and a new class of drugs Kurose, Takeshi Hamamoto, Yoshiyuki Seino, Yutaka J Diabetes Investig Editorial Several recent prospective cardiovascular clinical trials completed with newly developed drugs for the treatment of type 2 diabetes mellitus have been published. Caution must be used when interpreting these studies.[Image: see text] John Wiley and Sons Inc. 2017-03-30 2017-09 /pmc/articles/PMC5583954/ /pubmed/28130883 http://dx.doi.org/10.1111/jdi.12635 Text en © 2017 The Authors. Journal of Diabetes Investigation published by Asian Association for the Study of Diabetes (AASD) and John Wiley & Sons Australia, Ltd This is an open access article under the terms of the Creative Commons Attribution‐NonCommercial‐NoDerivs (http://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.
spellingShingle Editorial
Kurose, Takeshi
Hamamoto, Yoshiyuki
Seino, Yutaka
Evaluation of large‐scale clinical trials on cardiovascular disease risk in patients with type 2 diabetes mellitus treated with dipeptidyl peptidase 4 inhibitors and a new class of drugs
title Evaluation of large‐scale clinical trials on cardiovascular disease risk in patients with type 2 diabetes mellitus treated with dipeptidyl peptidase 4 inhibitors and a new class of drugs
title_full Evaluation of large‐scale clinical trials on cardiovascular disease risk in patients with type 2 diabetes mellitus treated with dipeptidyl peptidase 4 inhibitors and a new class of drugs
title_fullStr Evaluation of large‐scale clinical trials on cardiovascular disease risk in patients with type 2 diabetes mellitus treated with dipeptidyl peptidase 4 inhibitors and a new class of drugs
title_full_unstemmed Evaluation of large‐scale clinical trials on cardiovascular disease risk in patients with type 2 diabetes mellitus treated with dipeptidyl peptidase 4 inhibitors and a new class of drugs
title_short Evaluation of large‐scale clinical trials on cardiovascular disease risk in patients with type 2 diabetes mellitus treated with dipeptidyl peptidase 4 inhibitors and a new class of drugs
title_sort evaluation of large‐scale clinical trials on cardiovascular disease risk in patients with type 2 diabetes mellitus treated with dipeptidyl peptidase 4 inhibitors and a new class of drugs
topic Editorial
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5583954/
https://www.ncbi.nlm.nih.gov/pubmed/28130883
http://dx.doi.org/10.1111/jdi.12635
work_keys_str_mv AT kurosetakeshi evaluationoflargescaleclinicaltrialsoncardiovasculardiseaseriskinpatientswithtype2diabetesmellitustreatedwithdipeptidylpeptidase4inhibitorsandanewclassofdrugs
AT hamamotoyoshiyuki evaluationoflargescaleclinicaltrialsoncardiovasculardiseaseriskinpatientswithtype2diabetesmellitustreatedwithdipeptidylpeptidase4inhibitorsandanewclassofdrugs
AT seinoyutaka evaluationoflargescaleclinicaltrialsoncardiovasculardiseaseriskinpatientswithtype2diabetesmellitustreatedwithdipeptidylpeptidase4inhibitorsandanewclassofdrugs

Ejemplares similares